Chugai Pharmaceutical is conducting a phase one interventional ‘basket’ study to investigate the safety, tolerability, and efficacy of RAY121, an inhibitor of the classical complement pathway in the immune system. Participants are eligible for this study if they have at least one of the following autoimmune conditions: antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or immune thrombocytopenia (ITP).
Participants must be between the ages of 18-75 years. For those with ITP, having a platelet count less than 30,000 is another requirement for study participation.
USA, Australia, Austria, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Portugal, Romania, Spain, Taiwan, and Turkey
Actively Recruiting
Pfizer is conducting a phase 2 multicenter study to look at the safety and efficacy of using a drug called PF-06835375 for treatment of adults (between 18-70 years) with persistent or chronic primary ITP. This drug is administered either intravenously or subcutaneously, however in this trial subcutaneous injection would be the method of drug delivery. The drug acts by targeting a C-X-C chemokine receptor type 5 (CXCR5) inhibitor. Eligible participants have on-going ITP with a platelet count less than 50,000.
Canada, USA, Australia, Czechia, Hungary, and United Kingdom
https://classic.clinicaltrials.gov/ct2/show/NCT05070845
Actively Recruiting
Alpine Immune Sciences is conducting a Phase 1b Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of a new treatment for immune thrombocytopenia (and other autoimmune cytopenias) called Povetacicept (also known as APLN-303). This study is open to adults with persistent or chronic ITP. Povetacicept is a is a dual B cell cytokine antagonist engineered to inhibit BAFF (BLyS) and APRIL which are clinically validated cytokine pathways that play a key role in B cell development, differentiation, and survival. The drug will be provided to participants every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period. Adult participants must have shown failure to at least two previous treatments for ITP, including exposure to a TPO-RA, unless otherwise contraindicated or unavailable to them. Participants must also have a documented platelet count of less than 30,000 µL.
USA, Australia, Austria, Canada, Germany, Italy, Norway, Spain, Turkey, and the United Kingdom
https://www.clinicaltrials.gov/study/NCT05757570?term=%20Povetacicept%20&rank=2
Actively Recruiting
This global ITP registry study is FDA approved and developed in partnership with the National Organization for Rare Disorders (NORD) to follow ITP patients of all ages, in all phases of disease to learn more about the natural history of ITP. The goal of the registry is to learn more about the clinical characteristics of ITP, the incidence of co-morbidities, treatment patterns, adverse outcomes, how quality of life is impacted, how family and socioeconomics is affected, and how ITP patients respond to COVID-19 and vaccinations. Note: The registry is in English only, currently.
USA, Canada, International (all places).
https://www.pdsa.org/registry.html
Recruiting
This is a randomized double-blind pilot study to determine the clinical utility of using Oseltamirvir compared to placebo in the treatment of ITP. Oseltamivir is an attractive drug for ITP since it specifically targets a pathophysiologic mechanism that appears to be important for the development of ITP and has a benign side effect profile compared to standard ITP therapy. Eligibility includes adults with ITP who have not had a sustained response to other available treatments.
Canada
https://clinicaltrials.gov/ct2/show/NCT03520049?recrs=a&cond=ITP&draw=4
Status: Unknown